These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

381 related items for PubMed ID: 21617239

  • 1. Bevacizumab in first-line therapy of metastatic colorectal cancer: a retrospective comparison of FOLFIRI and XELIRI.
    Ocvirk J, Rebersek M, Boc M.
    Anticancer Res; 2011 May; 31(5):1777-82. PubMed ID: 21617239
    [Abstract] [Full Text] [Related]

  • 2. XELIRI plus bevacizumab compared with FOLFIRI plus bevacizumab as first-line setting in patients with metastatic colorectal cancer: experiences at two-institutions.
    Uygun K, Bilici A, Kaya S, Oven Ustaalioglu BB, Yildiz R, Temiz S, Seker M, Aksu G, Cabuk D, Gumus M.
    Asian Pac J Cancer Prev; 2013 May; 14(4):2283-8. PubMed ID: 23725128
    [Abstract] [Full Text] [Related]

  • 3. Efficacy and safety of bevacizumab-based combination regimens in patients with previously untreated metastatic colorectal cancer: final results from a randomised phase II study of bevacizumab plus 5-fluorouracil, leucovorin plus irinotecan versus bevacizumab plus capecitabine plus irinotecan (FNCLCC ACCORD 13/0503 study).
    Ducreux M, Adenis A, Pignon JP, François E, Chauffert B, Ichanté JL, Boucher E, Ychou M, Pierga JY, Montoto-Grillot C, Conroy T.
    Eur J Cancer; 2013 Apr; 49(6):1236-45. PubMed ID: 23352604
    [Abstract] [Full Text] [Related]

  • 4. Bevacizumab combined with chemotherapy in the second-line treatment of metastatic colorectal cancer: results from the phase II BEVACOLOR study.
    Bennouna J, Borg C, Delord JP, Husseini F, Trillet-Lenoir V, Faroux R, François E, Ychou M, Goldwasser F, Bouché O, Senellart H, Kraemer S, Douillard JY.
    Clin Colorectal Cancer; 2012 Mar; 11(1):38-44. PubMed ID: 21803002
    [Abstract] [Full Text] [Related]

  • 5. Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second-line therapy for metastatic colorectal cancer (AXEPT): a multicentre, open-label, randomised, non-inferiority, phase 3 trial.
    Xu RH, Muro K, Morita S, Iwasa S, Han SW, Wang W, Kotaka M, Nakamura M, Ahn JB, Deng YH, Kato T, Cho SH, Ba Y, Matsuoka H, Lee KW, Zhang T, Yamada Y, Sakamoto J, Park YS, Kim TW.
    Lancet Oncol; 2018 May; 19(5):660-671. PubMed ID: 29555258
    [Abstract] [Full Text] [Related]

  • 6. Capecitabine plus irinotecan versus 5-FU/leucovorin plus irinotecan in the treatment of colorectal cancer: a meta-analysis.
    Guo Y, Shi M, Shen X, Yang C, Yang L, Zhang J.
    Clin Colorectal Cancer; 2014 Jun; 13(2):110-8. PubMed ID: 24461997
    [Abstract] [Full Text] [Related]

  • 7. Capecitabine plus Irinotecan (XELIRI regimen) compared to 5-FU/LV plus Irinotecan (FOLFIRI regimen) as neoadjuvant treatment for patients with unresectable liver-only metastases of metastatic colorectal cancer: a randomised prospective phase II trial.
    Skof E, Rebersek M, Hlebanja Z, Ocvirk J.
    BMC Cancer; 2009 Apr 22; 9():120. PubMed ID: 19386096
    [Abstract] [Full Text] [Related]

  • 8. Bevacizumab with FOLFIRI or XELIRI in the First-line Therapy of Metastatic Colorectal Carcinoma: Results from Czech Observational Registry.
    Kocakova I, Melichar B, Kocak I, Bortlicek Z, Büchler T, Dusek L, Petruzelka L, Kohoutek M, Prausová J, Finek J, Mohelnikova-Duchonova B, Vyzula R.
    Anticancer Res; 2015 Jun 22; 35(6):3455-61. PubMed ID: 26026110
    [Abstract] [Full Text] [Related]

  • 9. Differences in efficacy and safety between capecitabine and infusional 5-fluorouracil when combined with irinotecan for the treatment of metastatic colorectal cancer.
    Montagnani F, Chiriatti A, Licitra S, Aliberti C, Fiorentini G.
    Clin Colorectal Cancer; 2010 Oct 22; 9(4):243-7. PubMed ID: 20920997
    [Abstract] [Full Text] [Related]

  • 10. XELOX plus bevacizumab vs. FOLFIRI plus bevacizumab treatment for first-line chemotherapy in metastatic colon cancer: a retrospective study of the Anatolian Society of Medical Oncology.
    Duran AO, Karaca H, Besiroglu M, Bayoglu IV, Menekse S, Yapici HS, Yazilitas D, Bahceci A, Uysal M, Sevinc A, Hacibekiroglu I, Aksoy A, Tanriverdi O, Arpaci E, Inanc M, Dane F, Ozkan M.
    Asian Pac J Cancer Prev; 2014 Oct 22; 15(23):10375-9. PubMed ID: 25556478
    [Abstract] [Full Text] [Related]

  • 11. Phase IV study of bevacizumab in combination with infusional fluorouracil, leucovorin and irinotecan (FOLFIRI) in first-line metastatic colorectal cancer.
    Sobrero A, Ackland S, Clarke S, Perez-Carrión R, Chiara S, Gapski J, Mainwaring P, Langer B, Young S, AVIRI Trial investigators.
    Oncology; 2009 Oct 22; 77(2):113-9. PubMed ID: 19628950
    [Abstract] [Full Text] [Related]

  • 12. A phase I/II study of biweekly capecitabine and irinotecan plus bevacizumab as second-line chemotherapy in patients with metastatic colorectal cancer.
    Suenaga M, Mizunuma N, Matsusaka S, Shinozaki E, Ozaka M, Ogura M, Chin K, Yamaguchi T.
    Drug Des Devel Ther; 2015 Oct 22; 9():1653-62. PubMed ID: 25834402
    [Abstract] [Full Text] [Related]

  • 13. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study.
    Fuchs CS, Marshall J, Mitchell E, Wierzbicki R, Ganju V, Jeffery M, Schulz J, Richards D, Soufi-Mahjoubi R, Wang B, Barrueco J.
    J Clin Oncol; 2007 Oct 20; 25(30):4779-86. PubMed ID: 17947725
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. A randomised, double-blind, placebo-controlled multi-centre phase III trial of XELIRI/FOLFIRI plus simvastatin for patients with metastatic colorectal cancer.
    Lim SH, Kim TW, Hong YS, Han SW, Lee KH, Kang HJ, Hwang IG, Lee JY, Kim HS, Kim ST, Lee J, Park JO, Park SH, Park YS, Lim HY, Jung SH, Kang WK.
    Br J Cancer; 2015 Nov 17; 113(10):1421-6. PubMed ID: 26505681
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. [Recent results of irinotecan therapy in colorectal cancer].
    Láng I, Hitre E.
    Magy Onkol; 2004 Nov 17; 48(4):281-8. PubMed ID: 15655572
    [Abstract] [Full Text] [Related]

  • 19. XELIRI-bevacizumab versus FOLFIRI-bevacizumab as first-line treatment in patients with metastatic colorectal cancer: a Hellenic Cooperative Oncology Group phase III trial with collateral biomarker analysis.
    Pectasides D, Papaxoinis G, Kalogeras KT, Eleftheraki AG, Xanthakis I, Makatsoris T, Samantas E, Varthalitis I, Papakostas P, Nikitas N, Papandreou CN, Pentheroudakis G, Timotheadou E, Koutras A, Sgouros J, Bafaloukos D, Klouvas G, Economopoulos T, Syrigos KN, Fountzilas G.
    BMC Cancer; 2012 Jun 29; 12():271. PubMed ID: 22748098
    [Abstract] [Full Text] [Related]

  • 20. Cetuximab plus XELIRI or XELOX for first-line therapy of metastatic colorectal cancer.
    Moosmann N, Heinemann V.
    Clin Colorectal Cancer; 2008 Mar 29; 7(2):110-7. PubMed ID: 18501070
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.